Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 5, 2003. The report details specific corporate actions regarding share re-purchases and changes in directors' interests in the company's ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share transactions:
- Share Re-purchase: 2,290,000 ordinary shares purchased for cancellation on March 4, 2003, at a price of 1,087.04 pence per share.
- Trust Transactions: The GlaxoSmithKline Employee Trust sold shares on February 28, 2003, at approximately 1,078.35 pence per share, and on March 3, 2003, at approximately 1,143.35 pence and 1,143.00 pence per share.
Material Changes
The filing reports the following material changes in share capital and director interests:
- Capital Reduction: The company reduced its share count by 2,290,000 shares through a buyback authorized by shareholders at the May 20, 2002, Annual General Meeting.
- Director Interests: Changes were recorded in the GlaxoSmithKline Employee Trust, which holds shares for the benefit of employees. Directors Dr. J-P Garnier and Mr. J D Coombe hold interests in the trust shares in the same capacity as other employees. Specific transactions included sales and transfers to participants of the Glaxo Wellcome 1999 Long Term Incentive Plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items beyond the routine disclosure of share transactions and director interests.
Investor Verification Checklist
- Verify the total number of shares remaining outstanding following the cancellation of 2,290,000 shares.
- Confirm the total value of the share buyback program utilized under the May 2002 authorization.
- Review the full details of the GlaxoSmithKline Employee Trust holdings to understand the aggregate interest of directors Dr. J-P Garnier and Mr. J D Coombe.
- Check subsequent filings for the impact of these transactions on earnings per share (EPS).